Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note

Bristol Myers Squibb (BMY) recently closed at $44.16, underperforming the S&P 500 with a 1.67% daily decline and a 4.87% monthly decrease. For its upcoming October 30, 2025 earnings report, the company anticipates an 8.33% year-over-year EPS decline to $1.65 on $11.77 billion revenue, although full-year EPS is projected to surge by 465.22% to $6.5. BMY currently trades at a forward P/E of 6.91, a significant discount to its industry average of 19.48, but its PEG ratio of 2.3 exceeds the industry's 1.68, and it maintains a Zacks Rank #3 (Hold).

Analysis

Bristol Myers Squibb (BMY) is exhibiting significant near-term weakness, with its stock closing at $44.16, a 1.67% drop that underperformed the S&P 500. This trend extends to a one-month view, where the stock's 4.87% decline contrasts sharply with the S&P 500's 3.08% gain and its own Medical sector's modest 0.33% loss. The market's apprehension appears linked to the forthcoming earnings report, which projects a year-over-year decline in both quarterly earnings per share to $1.65 (-8.33%) and revenue to $11.77 billion (-1.03%). However, a significant disconnect exists with the full-year forecast, where analysts expect an extraordinary 465.22% surge in EPS to $6.50, even as full-year revenue is anticipated to fall by 2.06%. From a valuation perspective, BMY presents a mixed picture; its forward P/E ratio of 6.91 indicates a substantial discount relative to the industry average of 19.48, but its PEG ratio of 2.3 is unfavorably higher than the industry's 1.68, suggesting growth may be overvalued. The neutral sentiment is underscored by a stable Zacks Consensus EPS estimate over the past month, resulting in a Zacks Rank of #3 (Hold).

Key Decisions for Investors

• Investors should weigh the attractive forward P/E of 6.91 against the near-term headwinds of declining quarterly revenue and earnings, as well as a PEG ratio that suggests growth is priced at a premium to the industry.
• Closely scrutinize the upcoming October 30th earnings call for management's explanation of the drivers behind the forecasted 465.22% full-year EPS growth, as this is the primary bull case against a backdrop of negative near-term momentum.
• Given the stock's recent underperformance and the neutral Zacks 'Hold' rating, it may be prudent to await confirmation of the full-year earnings trajectory before initiating or adding to a position.